Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: Quantitative assessment by a morphometric method

Journal of Hepatology

Volumn 29, Issue 1, 1998, Pages 20-28

  Duchatelle, Veronique ^a   Marcellin, Patrick ^a   Giostra, Emile ^a   Bregeaud, Laurence ^a   Pouteau, Michele ^a   Boyer, Nathalie ^a   Auperin, Anne ^a   Guerret, Sylviane ^b   Erlinger, Serge ^a   Henin, Dominique ^a   Degott, Claude ^a  

^a BEAUJON HOSPITAL   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

Chronic hepatitis; Fibrosis; Hepatitis C; Interferon

Indexed keywords

ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032124863     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80174-8     Document Type: Article

References (26)

1. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized conrolled trial. N Engl J Med. 321:1989;1501-1506.
2. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med. 321:1989;1506-1510.
3. Omata M, Ito Y, Yokosuka O, Imazeki F, Uchiumi K, Takano S, et al. Histological changes of the liver by treatment of chronic non-A, non-B hepatitis with recombinant leukocyte interferon alpha. Comparison with histological changes in chronic hepatitis B. Dig Dis Sci. 34:1989;330-337.
4. Marcellin P, Boyer N, Giostra E, Degott C, Couroucé AM, Degos F, et al. Recombinant human alpha interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology. 13:1991;393-397.
5. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non B hepatitis. Gastroenterology. 101:1991;497-502.
6. Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, et al. Long term follow-up of patients with chronic hepatitis C treated with different doses of interferon-α2b. Hepatology. 18:1993;1300-1305.
7. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
8. Czaja MJ, Weiner FR, Ehgbali M, Giambrone MA, Eghbali M, Zern MA. Differential effects of gamma-interferon on collagen and fibronectin gene expression. J Biol Chem. 262:1987;13348-13351.
9. Czaja MJ, Weiner FR, Takahashi S, Giambrone MA, Van Der Meide PH, Schellekens H, et al. Gamma-interferon treatment inhibits collagen deposition in murine schistosomiasis. Hepatology. 10:1989;795-800.
10. Jimenez SA, Freundlich B, Rosenbloom J. Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest. 7:1984;1112-1116.
11. Schiff ER. Hepatic fibrosis: new therapeutic approaches. N Engl J Med. 324:1991;987-989.
12. Castilla A, Prieto J, Fausto N. Transforming growth factors β1 and α in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med. 324:1991;933-940.
13. Hiramatsu N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Haruna N, et al. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. J Hepatol. 22:1995;135-142.
14. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histologic grading and staging of chronic hepatitis. J Hepatol. 22:1995;696-699.
15. Jimenez W, Pares A, Caballeria J, Heredia J, Bruguera M, Torres M, et al. Measurement of fibrosis in needle liver biopsies: evaluation of a colorimetric method. Hepatology. 5:1985;815-818.
16. Manabe N, Chevallier M, Chossegros P, Causse X, Guerret S, Trepo C, et al. Interferon-α2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitive histological evaluation. Hepatology. 18:1993;1344-1349.
17. Marcellin P, Pouteau M, Martinot-Peignoux M, Degos F, Duchatelle V, Boyer N, et al. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology. 109:1995;156-165.
18. De Alava E, Camps J, Pardo-Mindan J, Garcia-Granero M, Munoz M, Sola J, et al. Histological outcome of chronic hepatitis C treated with a 12-month course of lymphoblastoid alfa interferon. Liver. 13:1993;73-79.
19. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy. Ann Intern Med. 127:1997;875-881.
20. Gressner AM. Cytokines and cellular crosstalk involved in the activation of fat-storing cells. J Hepatol. 22:1995;28-36. (Suppl. 2).
21. Desmoulière A, Tuchweber B, Gabbiani G. Role of the myofibroblast differentiation during liver fibrosis. J Hepatol. 22:1995;61-64. (Suppl. 2).
22. Capra F, Casaril M, Gabrielli GB, Tognella P, Rizzi A, Dolci L, et al. α-interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers. J Hepatol. 18:1993;112-118.
23. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanaagi M, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: relationship to genotypes of hepatitis C virus. Hepatology. 16:1992;293-299.
24. Lau JY, Davis GL, Kniffen J, Quian KP, Urdea M, Chan C, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis. Lancet. 341:1993;1501-1504.
25. Magrin S, Craxi A, Fabiano C, Simonetti RG, FIorentino G, Marino L, et al. Hepatitis C viremia in chronic liver disease: relationship to interferon alpha or corticosteroid treatment. Hepatology. 19:1994;273-279.
26. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, et al. Pretreatment serum HCV RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to alpha interferon therapy in chronic hepatitis C. Hepatology. 22:1995;1050-1056.